Dosages & Reactions

Interactions:

Acenocoumarol
Adverse Effect: Increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nitrendipine and Acenocoumarol should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Amiodarone
Adverse Effect: Atrioventricular block and slowing of sinus rate
Clinical Management: Concurrent use of amiodarone and Nitrendipine should be avoided in patients with sick sinus syndrome or partial AV (atrioventricular) block.
Atenolol
Adverse Effect: Hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Betaxolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Bisoprolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Carvedilol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Celecoxib
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Celiprolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Cimetidine
Adverse Effect: Increased nitrendipine concentrations and possible cardiovascular toxicity
Clinical Management: Monitor the cardiovascular response (blood pressure, heart rate) of Nitrendipine if cimetidine is added to the regimen. Dose reductions of up to 35% to 40% may be needed for diltiazem or nifedipine.
Digoxin
Adverse Effect: Increased serum digoxin concentrations and toxicity (nausea, vomiting, arrhythmias)
Clinical Management: Monitor patient for signs or symptoms of digitalis glycoside toxicity (nausea, vomiting, cardiac rhythm disturbance) and laboratory evidence of unacceptable increases in serum digoxin concentrations (therapeutic range: 0.8 to 2.0 ng/mL). Adjust the digoxin dose as required.
Esmolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Flurbiprofen
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ibuprofen
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ibuprofen Comb.
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Indomethacin
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ketoconazole
Adverse Effect: increased Nitrendipine serum concentrations and toxicity (dizziness, hypotension, flushing, headache, peripheral edema)
Clinical Management: Observe for development of toxicity associated with Nitrendipine (peripheral edema, dizziness, hypotension, flushing, headache). Consider reducing the dose of the Nitrendipine or withdrawing one of the agents.
Ketoprofen
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ketorolac
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Labetalol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Levobunolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Mefenamic Acid
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Meloxicam
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Metoprolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Nabumetone
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Naproxen
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Nimesulide
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Oxprenolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Oxyphenbutazone
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Paracetamol
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Paracetamol Comb.
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenacetin
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Phenindione
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nitrendipine and Phenindione should be monitored for excessive bleeding, especially from the gastrointestinal tract.
Phenylbutazone
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Pindolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Piroxicam
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Propranolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Rifampicin
Adverse Effect: Decreased nitrendipine efficacy
Tenoxicam
Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Timolol
Adverse Effect: hypotension and/or bradycardia
Clinical Management: If concurrent therapy is required, monitor cardiac function carefully, particularly in patients predisposed to heart failure.
Warfarin
Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Nitrendipine and Warfarin should be monitored for excessive bleeding, especially from the gastrointestinal tract.

Naloxone Hydrochloride

Naproxen

Neomycin Sulfate

Neostigmine Bromide

Niacin(nicotinic acid)

Nifedipine

Nitrofurantoin

Nitroprusside Sodium

Norepinephrine Bitartrate

Nortriptyline Hydrochloride

Nystatin

Nitrofurazone